BIOS Capital Management, LP

CIK: 0001813845Latest portfolio: $82.6M · Q4 2025

Holdings

6

Total Value

$82.6M

New Positions

1

Closed Positions

1

Top Holdings

#StockSharesValue% PortfolioChangeType
1
ACTUACTUATE THERAPEUTICS INC
10,049,996$61.5M74.44%
2
CGTXCOGNITION THERAPEUTICS INC
6,000,000$8.1M9.80%
3
IRDOPUS GENETICS INC
3,683,429$7.4M8.96%
4
LTRNLANTERN PHARMA INC
1,009,507$3.1M3.70%-6,208
5
RNTXREIN THERAPEUTICS INC
1,690,751$2.0M2.37%
6
INABIN8BIO INC
253,417$592K0.72%NEW

Quarterly Changes

New Positions

Closed Positions

Increased Positions

No increased positions

Decreased Positions

NameSharesChange
LTRN1.0M-6208

Sector Breakdown

Healthcare100.0% ($615058099740330.6T)

Filing History

QuarterFiling DatePortfolio ValueHoldings
Q4 2025Feb 13, 2026$82.6M9
Q3 2025Nov 12, 2025$88.9B9
Q2 2025Aug 12, 2025$72.6B9
Q1 2025May 14, 2025$79.2B9
Q4 2024Feb 10, 2025$95.9B9

Fund Information

CIK0001813845
Most Recent FilingFeb 13, 2026
Number of Filings5

BIOS Capital Management, LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $82.6M across 6 holdings. The largest position is ACTUATE THERAPEUTICS INC (ACTU), representing 74.4% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 1 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.